Why Use DEFINITY®? Product Support
Product Support
From product training and promotional programs, to experienced Medical Liasons and sales representatives, DEFINITY® is backed by world-class service and support.
Product Support Programs
- On-site product training by dedicated DEFINITY® Medical Liaisons
- Over 1,600 institutions have received DEFINITY® promotional programs
- Highly trained sales and clinical support personnel.
- Assistance with product-related reimbursement questions regarding DEFINITY®
(1-800-362-2668 x7995)
Lantheus Medical Imaging cannot guarantee coverage or payment for products or procedures. Payer policies can widely vary and third party payment for medical products and services is affected by numerous factors. It is always the provider's responsibility to determine and submit appropriate codes, charges, and modifiers for services rendered. For more specific information, contact your third-party payer directly in order to obtain up-to-date coverage, coding and payment information.
Medical Information to answer medical and technical questions about DEFINITY® (800–343–7851)
Click here for more contact information.
Industry Links
American College of Cardiology (ACC)
American Heart Association (AHE)
American Society of Echocardiography (ASE)
American Society of Echocardiography- Contrast Zone (ASE)
American
Institute of Ultrasound in Medicine (AIUM)
American
Registry of Diagnostic Medical Sonographers (ARDMS)
Canadian
Society of Diagnostic Medical Sonographers (CSDMS)
Radiological
Society of North America (RSNA)
Society
of Diagnostic Medical Sonography (SDMS)
Society
of Radiologists in Ultrasound (SRU)
INDICATIONS
Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.
CONTRAINDICATIONS
Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.
IMPORTANT SAFETY INFORMATION
WARNING: Serious Cardiopulmonary Reactions Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration.
|
In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration (see ADVERSE REACTIONS). The risk for these reactions may be increased among patients with pulmonary hypertension or unstable cardiopulmonary conditions. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.
Please See Full Prescribing Information and Letter to Healthcare Providers.
